Michael Boeckh

Active 1992–2025

242
Papers
41,873
Citations
119
h-index
231
i10-index

Citations

Citations per year for Michael Boeckh1983: 3 citations1989: 2 citations1991: 1 citations1993: 1 citations1994: 4 citations1996: 10 citations1997: 12 citations1998: 18 citations1999: 39 citations2000: 54 citations2001: 94 citations2002: 141 citations2003: 169 citations2004: 199 citations2005: 192 citations2006: 166 citations2007: 274 citations2008: 275 citations2009: 265 citations2010: 284 citations2011: 333 citations2012: 299 citations2013: 329 citations2014: 252 citations2015: 235 citations2016: 325 citations2017: 277 citations2018: 262 citations2019: 1,162 citations2020: 1,433 citations2021: 1,252 citations2022: 782 citations2023: 592 citations2024: 1,101 citations2025: 428 citations2026: 3 citations1984–1988: no citations, so these years are not shown1990: no citations, so this year is not shown1992: no citations, so this year is not shown1995: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,387 citing papers, 31.3% of this breakdownUnited Kingdom: 678 citing papers, 6.3% of this breakdownGermany: 673 citing papers, 6.2% of this breakdownFrance: 579 citing papers, 5.4% of this breakdownItaly: 492 citing papers, 4.5% of this breakdownChina: 409 citing papers, 3.8% of this breakdownSpain: 384 citing papers, 3.5% of this breakdownCanada: 381 citing papers, 3.5% of this breakdownAustralia: 334 citing papers, 3.1% of this breakdownSwitzerland: 330 citing papers, 3.1% of this breakdownNetherlands: 327 citing papers, 3% of this breakdownJapan: 252 citing papers, 2.3% of this breakdown
0%31.3%Other 24%

Fields

  • Medicine88%
  • Immunology and Microbiology4.3%
  • Biochemistry, Genetics and Molecular Biology4%
  • Mathematics0.7%
  • Health Professions0.6%
  • Agricultural and Biological Sciences0.5%
  • Other1.9%

Topics

  • Cytomegalovirus and herpesvirus research9.5%
  • Hematopoietic Stem Cell Transplantation5.9%
  • Herpesvirus Infections and Treatments4.5%
  • Antifungal resistance and susceptibility4.2%
  • Respiratory viral infections research3.5%
  • SARS-CoV-2 and COVID-19 Research3.4%
  • Other69%

Coauthors

All papers

Open in search
  1. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 1,206

  2. Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy

    Authors: , , , , , , , , , - Blood 2017 cited by 566

  3. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

    Authors: , , , , , , , , , - Clinical Infectious Diseases 2016 cited by 948

  4. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

    Authors: , , , , , , , , - Biology of Blood and Marrow Transplantation 2009 cited by 1,779

  5. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood 2016 cited by 547

  6. Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts

    Authors: , , , , , , , , , , , , , , , - Annals of Internal Medicine 2020 cited by 278

  7. Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation

    Authors: , , , , , , , , , , , - New England Journal of Medicine 2010 cited by 1,479

  8. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

    Authors: , , , , , , , , , , , , , , - The Lancet Haematology 2016 cited by 420

  9. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation

    Authors: , , , , , , , , , , , , , , - Blood 2021 cited by 161

  10. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

    Authors: , , , , , , , , , , - Clinical Infectious Diseases 2018 cited by 219

  11. Liquid Biopsy for Invasive Mold Infections in Hematopoietic Cell Transplant Recipients With Pneumonia Through Next-Generation Sequencing of Microbial Cell-Free DNA in Plasma

    Authors: , , , , , , , , , , , , - Clinical Infectious Diseases 2020 cited by 104

  12. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors

    Authors: , , , , , , , , , - JAMA 2020 cited by 171

  13. American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation

    Authors: , , , , , , , , - Transplantation and Cellular Therapy 2021 cited by 128

  14. Cytomegalovirus Reactivation in Critically Ill Immunocompetent Patients

    Authors: , , , , , , , , , , - JAMA 2008 cited by 577

  15. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

    Authors: , , - Blood 2020 cited by 164

  16. Cytomegalovirus: pathogen, paradigm, and puzzle

    Authors: , - Journal of Clinical Investigation 2011 cited by 360

  17. Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michelle Wong, Dana G. Wolf - Clinical Infectious Diseases 2024 cited by 149

  18. Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of the American Thoracic Society 2023 cited by 79

  19. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients

    Authors: , , , , , , - Clinical Infectious Diseases 2017 cited by 140

  20. Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation

    Authors: , , - Clinical Microbiology Reviews 2020 cited by 118

  21. A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract

    Authors: , , , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2019 cited by 76

  22. The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality

    Authors: , , , , , , , , , , , , , , - Blood 2017 cited by 173

  23. Serial Quantitation of Plasma Microbial Cell-Free DNA Before and After Diagnosis of Pulmonary Invasive Mold Infections After Hematopoietic Cell Transplant

    Authors: , , , , , , , , , - The Journal of Infectious Diseases 2023 cited by 43

  24. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

    Authors: , , , , , , , , , , , , , , , , , , , - Immunity 2020 cited by 441